Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate efficacy and safety of clobazam, a 1,5-benzodiazepine, as adjunctive therapy for Lennox-Gastaut syndrome (LGS). METHODS: Patients aged 2-60 years were randomized to placebo or clobazam 0.25, 0.5, or 1.0 mg/kg/day. Study consisted of 4-week baseline, 3-week titration, and 12-week maintenance phases, followed by a 2- or 3-week taper or continuation in an open-label extension. Primary endpoint was percentage decrease in mean weekly drop seizure rates during maintenance vs baseline phases for modified intention-to-treat (mITT) population. Secondary outcomes included other seizure types, responder rates, and physicians' and caregivers' global assessments. RESULTS: A total of 305 patients were screened, 238 were randomized, and 217 composed the mITT population. Of patients enrolled after a protocol amendment, 125/157 (79.6%) completed. Average weekly drop seizure rates decreased 12.1% for placebo vs 41.2% (p = 0.0120), 49.4% (p = 0.0015), and 68.3% (p < 0.0001) for the clobazam 0.25-, 0.5-, and 1.0-mg/kg/day groups. Responder rates (≥50%) were 31.6% (placebo) vs 43.4% (p = 0.3383), 58.6% (p = 0.0159), and 77.6% (p < 0.0001) for clobazam 0.25-, 0.5-, and 1.0-mg/kg/day groups. Physicians' and caregivers' assessments indicated clobazam significantly improved symptoms. Somnolence, pyrexia, upper respiratory infections, and lethargy were the most frequent adverse events reported for clobazam. CONCLUSIONS: Clobazam significantly decreased weekly drop seizure rates in LGS. No new safety signals were identified. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that clobazam as adjunctive therapy is efficacious, in a dosage-dependent manner, in reducing mean weekly drop seizure rates of patients with LGS over 12 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics
Riss, J., Cloyd, J., Gates, J., & Collins, S. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01004.x · Cited by 511
Efficacy of Felbamate in Childhood Epileptic Encephalopathy (Lennox-Gastaut Syndrome)
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301073280105 · Cited by 407
A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome
Sachdeo, R. C., Glauser, T. A., Ritter, F., Reife, R., Lim, P., Pledger, G., & the Topiramate YL Study Group (1999) · Neurology · doi:10.1212/wnl.52.9.1882 · Cited by 380
Lamotrigine for Generalized Seizures Associated with the Lennox–Gastaut Syndrome
Motte, J., Trevathan, E., Arvidsson, J. F. V., Barrera, M. N., Mullens, E. L., & Manasco, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712183372504 · Cited by 359
Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome
Glauser, T., Kluger, G., Sachdeo, R., Krauss, G., Perdomo, C., & Arroyo, S. (2008) · Neurology · doi:10.1212/01.wnl.0000303813.95800.0d · Cited by 356
Lamotrigine for Generalized Seizures Associated with the Lennox–Gastaut Syndrome
Trevathan, E., Mullens, E. L., & Manasco, P. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809173391218 · Cited by 194
Treatment of Lennox-Gastaut syndrome
Hancock, E. C., & Cross, J. H. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003277.pub3 · Cited by 187
Antiepileptic Properties of Clobazam, a 1–5 Benzodiazepine, in Man
Gastaut, H., & Low, M. D. (1979) · Epilepsia · doi:10.1111/j.1528-1157.1979.tb04825.x · Cited by 144
Clobazam in the treatment of Lennox‐Gastaut syndrome
Conry, J. A., Ng, Y., Paolicchi, J., Kernitsky, L., Mitchell, W. G., Ritter, F. J., Collins, S. D., Tracy, K. A., Kormany, W. N., Abdulnabi, R., et al. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01935.x · Cited by 136
Self-citationNg, Y., & Collins, S. D. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.002 · Cited by 110
Self-citationClobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti
(1991) · Epilepsia · doi:10.1111/j.1528-1157.1991.tb04670.x · Cited by 102
Clobazam as adjunctive treatment in refractory epilepsy.
Allen, J. W., Oxley, J. R., Robertson, M. M., Trimble, M., Richens, A., & Jawad, S. (1983) · BMJ · doi:10.1136/bmj.286.6373.1246 · Cited by 81
Koeppen, D., Baruzzi, A., Capozza, M., Chauvel, P., Courjon, J., Favel, P., Harmant, J., Lorenz, H., Oiler, F. V. L., Procaccianti, G., et al. (1987) · Epilepsia · doi:10.1111/j.1528-1157.1987.tb03678.x · Cited by 74
Treatment of Infantile Spasms and Lennox‐Gastaut Syndrome with Clonazepam (Rivotril®)
VASSELLA, F., Pavlincova, E., Schneider, H., RUDIN, H. J., & Karbowski, K. (1973) · Epilepsia · doi:10.1111/j.1528-1157.1973.tb03953.x · Cited by 61
Medical Management of Lennox-Gastaut Syndrome
Michoulas, A., & Farrell, K. (2010) · CNS Drugs · doi:10.2165/11530220-000000000-00000 · Cited by 40
Sugai, K. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.458005.x · Cited by 39
Clobazam monotherapy in drug naı̈ve adult patients with epilepsy
Mehndiratta, M., KRISHNAMURTHY, M., Rajesh, K., & Singh, G. (2003) · Seizure · doi:10.1016/s1059-1311(02)00263-7 · Cited by 39
Clobazam for the treatment of intractable childhood epilepsy
Jan, M. M., & Shaabat, A. O. (2000) · Neurosciences · doi:10.17712/1658-3183.1045 · Cited by 39
Clobazam in Long‐Term Epilepsy Treatment: Sustained Responders Versus Those Developing Tolerance
Singh, A., Guberman, A. H., & Boisvert, D. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb01617.x · Cited by 35
Clobazam as Add-on Therapy in Children with Epileptic Encephalopathy
Silva, R. C., Montenegro, M. A., Guerreiro, C. A. M., & Guerreiro, M. M. (2006) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100004996 · Cited by 29
The use of clobazam, midazolam, and nitrazepam in epilepsy
Shorvon, S. D. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb05109.x · Cited by 27
The Lennox-Gastaut Syndrome and Its Frontiers
Niedermeyer, E. (1986) · Clinical Electroencephalography · doi:10.1177/155005948601700306 · Cited by 22
Cited by
Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood, S. M., Roberts, C., Checketts, D., VanLandingham, K. E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714631 · Cited by 1,015
Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., Lyons, P. D., Taylor, A., Roberts, C., Sommerville, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30136-3 · Cited by 905
Cross, J. H., Auvin, S., Falip, M., Striano, P., & Arzimanoglou, A. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00505 · Cited by 205
“The effectiveness of CLB in the treatment of LGS was demonstrated in a placebo-controlled Phase III RCT conducted in 238 patients with LGS (44) (Table 2).”
BackgroundKnupp, K. G., Scheffer, I. E., Ceulemans, B., Sullivan, J. E., Nickels, K. C., Lagae, L., Guerrini, R., Zuberi, S. M., Nabbout, R., Riney, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0829 · Cited by 137
Hahn, C. D., Jiang, Y., Villanueva, V., Zolnowska, M., Arkilo, D., Hsiao, S., Asgharnejad, M., & Dlugos, D. (2022) · Epilepsia · doi:10.1111/epi.17367 · Cited by 81
Metadata
- Authors
- Ng, Y. T., Conry, J. A., Drummond, R., Stolle, J., & Weinberg, M. A.
- Venue
- Neurology
- Published
- 2011-10-11
- Volume
- 77
- Issue
- 15
- Pages
- 1473-1481
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2169966598
- Cited by
- 191
- References
- 24
- FWCI
- 9.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.